Group 1: Financial Performance - In 2024, the company achieved a revenue of 497.01 million yuan and a net profit of 38.61 million yuan, both showing a significant decline year-on-year [6][7] - In Q1 2025, the company reported a revenue of 176.34 million yuan and a net profit of 47.42 million yuan, indicating a substantial recovery due to prior adjustments and concentrated order deliveries [7] Group 2: Strategic Adjustments - The company has made strategic adjustments in response to adverse international trade policies, enhancing service capabilities and increasing R&D investments [2][3] - To mitigate risks from U.S. tariff policies, the company plans to upgrade its production base in Wisconsin, USA, by expanding capacity and improving service capabilities [3][10] Group 3: Environmental Commitment - In 2024, the company invested 41.50 million yuan in environmental protection, purchasing 14,925,000 kWh of green electricity, resulting in a reduction of CO2 emissions by 13,013,107.50 kg [4][5] Group 4: Market Outlook and Risks - The company acknowledges uncertainties in overseas business due to tariff policies, which may affect order acquisition and delivery cycles [5][8] - The global pharmaceutical market is expected to continue growing, with increasing demand for CDMO services, presenting potential growth opportunities for the company [8][13] Group 5: Shareholder Relations - The company emphasizes its commitment to protecting shareholder interests and will disclose any significant shareholding changes in accordance with regulations [8][13] - A cash dividend of 4 yuan per 10 shares is proposed for 2024, amounting to 48.18 million yuan, which exceeds the net profit for that year [13]
金凯生科(301509) - 2025年4月28日投资者关系活动记录表